Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies
Radhia M’kacher(Genopole (France)), Patrice Carde(Institut Gustave Roussy), Nathalie Déchamps(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Dima Jouni(Université Paris-Sud), Claire Borie(Inserm), William M. Hempel, T. Girinsky(Institut Gustave Roussy), Luc Morat(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Leonhard Heidingsfelder(Robert Bosch (Germany)), Bruno Colicchio(Université de Haute-Alsace), Lev Stimmer(University of Veterinary Medicine Hannover, Foundation), Géraldine Pottier(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Eric Laplagne, Corina Cuceu(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Noufϊssa Oudrhiri(Inserm), Mustafa Al Jawhari(Direction de la Recherche Fondamentale), Annelise Bennaceur‐Griscelli(Inserm), Jean Bourhis(University of Lausanne), Éric Jeandidier(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Thomas Mehrling, Alain Dieterlen(Université de Haute-Alsace), Jacques Bosq(Embody (France)), Steffen Junker(Aarhus University), Raphaël Boisgard(Université Paris-Sud), Aude Lenain(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Anne-Laure Bauchet(Ipsen (France)), Monika Frenzel(Commissariat à l'Énergie Atomique et aux Énergies Alternatives)
Cited by 8
Related Papers
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618